CAR T cells produced in vivo to treat cardiac injury

Fibrosis affects millions of people with cardiac disease. Treatment with modified mRNA-targeted LNPs reduced fibrosis and restored cardiac function after injury.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 We developed a therapeutic approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified messenger RNA (mRNA) in T cell–targeted lipid nanoparticles (LNPs).
• 2 The efficacy of these in vivo–reprogrammed CAR T cells was evaluated by injecting CD5-targeted LNPs into a mouse model of heart failure.
• 3 Efficient delivery of modified mRNA encoding the CAR to T lymphocytes was observed, which produced transient, effective CAR T cells in vivo.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: